open access

Vol 12, No 6 (2017)
Original Papers
Published online: 2017-12-29
Get Citation

The value of cancer antigen 125 (Ca 125) and copeptin as markers in patients with advanced heart failure

Anita Woźniak-Wiśniewska, Jan Błażejewski, Robert Bujak, Łukasz Wołowiec, Daniel Rogowicz, Władysław Sinkiewicz
DOI: 10.5603/FC.2017.0103
·
Folia Cardiologica 2017;12(6):537-542.

open access

Vol 12, No 6 (2017)
Original Papers
Published online: 2017-12-29

Abstract

Introduction. A search continues for new markers and new monitoring methods that would be useful in the management of patients with advanced heart failure (HF). Recent studies have shown increased levels of cancer antigen 125 (Ca 125) and copeptin in patients with HF which implies that they may be used as markers of HF. Material and methods. The aim of the study was to evaluate levels of potential HF markers in relation to established biochemical markers. The study included 60 patients who were admitted due to exacerbation of chronic New York Heart Association class III or IV systolic HF. Before administration of initial intravenous diuretic dose, blood samples were collected to determine levels of conventional prognostic factors (uric acid, B-type natriuretic peptide [BNP]) and novel HF biomarkers (Ca 125, copeptin). Results. On admission, BNP level (median 1166.50 pg/mL [636.00–2068.50]) and uric acid level (9.497 ± 2.426 mg/ dL) in patients with HF was significantly higher compared to respective normal values. Ca 125 level (median 88.71 U/mL [29.28–169.00]) was also significantly increased, and copeptin level was significantly higher compared to the control group (median 96.55 vs 7.05 pg/mL, p < 0.0001). In additional, a statistically significant correlation between baseline BNP and Ca 125 levels (r = 0.48, p < 0.001) was observed. No correlations were found between baseline levels of copeptin and BNP or uric acid. Conclusion. In patients with chronic HF, several pathomechanisms are operating, which may be indicated by increased levels of several markers, including both conventional and new ones. Higher levels of Ca 125 were observed in patients with acute decompensated HF, even though these patients did not have a malignancy. However, Ca 125 did not exceed the prognostic value of BNP due to its low specificity. Despite different pathomechanisms of BNP and Ca 125 level elevations, a correlation was found between these markers, which might indicate a complex pathophysiology of HF in the studied group.

Abstract

Introduction. A search continues for new markers and new monitoring methods that would be useful in the management of patients with advanced heart failure (HF). Recent studies have shown increased levels of cancer antigen 125 (Ca 125) and copeptin in patients with HF which implies that they may be used as markers of HF. Material and methods. The aim of the study was to evaluate levels of potential HF markers in relation to established biochemical markers. The study included 60 patients who were admitted due to exacerbation of chronic New York Heart Association class III or IV systolic HF. Before administration of initial intravenous diuretic dose, blood samples were collected to determine levels of conventional prognostic factors (uric acid, B-type natriuretic peptide [BNP]) and novel HF biomarkers (Ca 125, copeptin). Results. On admission, BNP level (median 1166.50 pg/mL [636.00–2068.50]) and uric acid level (9.497 ± 2.426 mg/ dL) in patients with HF was significantly higher compared to respective normal values. Ca 125 level (median 88.71 U/mL [29.28–169.00]) was also significantly increased, and copeptin level was significantly higher compared to the control group (median 96.55 vs 7.05 pg/mL, p < 0.0001). In additional, a statistically significant correlation between baseline BNP and Ca 125 levels (r = 0.48, p < 0.001) was observed. No correlations were found between baseline levels of copeptin and BNP or uric acid. Conclusion. In patients with chronic HF, several pathomechanisms are operating, which may be indicated by increased levels of several markers, including both conventional and new ones. Higher levels of Ca 125 were observed in patients with acute decompensated HF, even though these patients did not have a malignancy. However, Ca 125 did not exceed the prognostic value of BNP due to its low specificity. Despite different pathomechanisms of BNP and Ca 125 level elevations, a correlation was found between these markers, which might indicate a complex pathophysiology of HF in the studied group.
Get Citation

Keywords

heart failure, biomarkers, Ca 125, copeptin, BNP

About this article
Title

The value of cancer antigen 125 (Ca 125) and copeptin as markers in patients with advanced heart failure

Journal

Folia Cardiologica

Issue

Vol 12, No 6 (2017)

Pages

537-542

Published online

2017-12-29

DOI

10.5603/FC.2017.0103

Bibliographic record

Folia Cardiologica 2017;12(6):537-542.

Keywords

heart failure
biomarkers
Ca 125
copeptin
BNP

Authors

Anita Woźniak-Wiśniewska
Jan Błażejewski
Robert Bujak
Łukasz Wołowiec
Daniel Rogowicz
Władysław Sinkiewicz

References (28)
  1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011; 8(1): 30–41.
  2. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003; 41(10): 1805–1811.
  3. Morgenthaler NG, Struck J, Jochberger S, et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008; 19(2): 43–49.
  4. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007; 115(16): 2103–2110.
  5. Piechota W, Piechota W. Wielomarkerowa ocena ryzyka w niewydolności serca. Kardiologia po Dyplomie. 2006; 5: 93–97.
  6. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004; 43(4): 635–641.
  7. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998; 351(9095): 9–13.
  8. Gackowski A, Isnard R, Piwowarska W, et al. Peptyd natriuretyczny typu B (BNP)- nowa metoda diagnostyczna w kardiologii? Kardiol Pol. 2002; 56: 644–649.
  9. Kaufman M, Guglin M. Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev. 2013; 18(2): 177–186.
  10. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009; 2(6): 556–562.
  11. Faggiano P, D'Aloia A, Brentana L, et al. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail. 2005; 7(1): 57–61.
  12. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003; 41(10): 1805–1811.
  13. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46(10): 1785–1791.
  14. Goldsmith SR, Francis GS, Cowley AW, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983; 1(6): 1385–1390.
  15. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52(1): 112–119.
  16. Miller WL, Hartman KA, Grill DE, et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart. 2012; 98(5): 389–394.
  17. Balling L, Kistorp C, Schou M, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail. 2012; 18(5): 351–358.
  18. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008; 52(4): 266–272.
  19. Voors AA, von Haehling S, Anker SD, et al. OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009; 30(10): 1187–1194.
  20. Duman D, Palit F, Simsek E, et al. Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail. 2008; 10(6): 556–559.
  21. Chen YX, Wang XQ, Fang CF, et al. Value of BNP and tumour marker CA125 in patients with heart failure. Acta Cardiol. 2008; 63(4): 501–506.
  22. Núñez J, Núñez E, Sanchis J, et al. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol. 2012; 159(1): 21–28.
  23. Folga A, Filipiak KJ, Mamcarz A, et al. Simultaneous predictive value of NT-proBNP and CA-125 in patients newly diagnosed with advanced heart failure: preliminary results. Arch Med Sci. 2012; 8(4): 637–643.
  24. Núñez J, Núñez E, Consuegra L, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart. 2007; 93(6): 716–721.
  25. Nägele H, Bahlo M, Klapdor R, et al. CA 125 and its relation to cardiac function. Am Heart J. 1999; 137(6): 1044–1049.
  26. Balling L, Kistorp C, Schou M, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail. 2012; 18(5): 351–358.
  27. Faggiano P, Valle R, Aspromonte N, et al. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification. Int J Cardiol. 2010; 140(1): 88–94.
  28. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab. 2006; 91(11): 4381–4386.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl